The molecular basis of clinical diversity in glycogenosis type II (Pompe's disease) was investigated by comparing the nature of acid a-glucosidase deficiency in cultured fibroblasts from 30 patients. Biosynthetic forms of acid a-glucosidase with different molecular mass were separated electrophoretically and identified by immunoblotting. Immuno-electron microscopy was employed to determine the intracellular localization of mutant enzyme. Our studies illustrate that maturation of acid a-glucosidase is associated with transport to the lysosomes. Deficiency of catalytically active mature enzyme in lysosomes is common to all clinical phenotypes but, in the majority of cases, is more profound in early onset than in late onset forms of the disease. Thus, the results suggest that the clinical course of glycogenosis type II is primarily determined by the amount of functional acid a-glucosidase. The role of secondary factors can, however, not be excluded because three adult patients were identified with very low activity and little enzyme in the lysosomes.
Introduction
Glycogenosis type II is an autosomal recessive disorder characterized by lysosomal accumulation ofglycogen and deficiency of acid a-glucosidase (EC 3.2.1.20) (1) . Cardiomegaly, hepatomegaly, and severe hypotonia are typical symptoms of the infantile form ofthe disease, which is rapidly progressive and fatal in the first or second year of life (2, 3) . When glycogenosis type II presents at a more advanced age, the symptoms are generally limited to weakness of the skeletal muscles. Patients with these milder forms of the disease have been classified as juvenile or adult variants (3) (4) (5) (6) .
Some studies on skeletal muscle biopsy material (7), leukocytes (8, 9) , cultured skin fibroblasts (10, 11) , and urine (12) from patients with glycogenosis type II have suggested that the residual activity ofacid a-glucosidase is an important parameter in determining the clinical phenotype. Other studies, however, in which very low enzyme activities were measured in cultured skin fibroblasts and muscle tissue from adult patients, dispute the correlation between the acid a-glucosidase activity and the expression of the disease (13) (14) (15) (16) . Particular attention has been paid to a possible role of neutral maltases in influencing the pathogenesis of glycogenosis type II, but the results have been contradictory and inconclusive (15) (16) (17) (18) .
To evaluate the contribution of secondary factors, it is essential to determine at first to what extent clinical diversity is caused by heterogeneity of the acid a-glucosidase locus itself. Indicative of genetic heterogeneity are differences in the acid aglucosidase activity and the amount of immunologically detectable enzyme protein among clinical variants (10, 11, 13, 16, 19) . More recent studies on the biosynthesis ofacid a-glucosidase in mutant fibroblasts have given additional and more detailed information on the occurrence of a variety of molecular defects that can lead to glycogenosis type 11 (14, 20, 21) . However, the number of patients in these studies has been too small to investigate properly the relation between specific molecular defects and clinical variation. This question is the subject of the present investigation, in which 30 cases of glycogenosis type II were surveyed. Immunoblotting was used to characterize and quantitate the biosynthetic forms of acid a-glucosidase in the patient's cultured fibroblasts, and the enzymatic activity was determined.
Immuno-electron microscopy was employed to study the in situ localization of the mutant enzymes.
Novel defects in the biosynthesis of acid a-glucosidase were discovered. By combining assessment of clinical phenotype, intracellular localization of acid a-glucosidase, and enzymatic activity, it is concluded that the amount of functional enzyme in the lysosome is the primary but probably not 4 h in the absence of label before harvesting. Homogenates were prepared and acid a-glucosidase was analyzed in SDS-polyacrylamide gels after immunoprecipitation as described by Hasilik and Neufeld (28, 29) . Immunocytochemistry. 3-d confluent cultures (3-4 X 106 cells in total) were harvested with 0.25% trypsin in phosphate buffered saline (PBS), pH 7.0. The period of trypsinization, at 370C was < 1 min, and detachment of cells was promoted by shaking. The action oftrypsin was terminated by resuspending the cells in fresh culture medium containing 10% FCS. Cells were collected by centrifugation, washed two times with fresh medium, and then resuspended in 25 ml of culture medium. They were left for 2 h at 370C in a rotating tube to recover from possible trypsinization damage. Finally, the cells were pelleted and prepared for immunocytochemistry as described before (30) .
Ultrathin frozen sections were incubated with affinity-purified antibodies against placental acid a-glucosidase (14) , and antibody-antigen complexes were visualized by a second incubation with goat anti-rabbit immunoglobulins coupled to colloidal gold.
Results
The patients from whom cell lines were obtained were classified as infantile, juvenile, or adult variants of glycogenosis type II according to age ofonset, progression, and severity ofsymptoms (Table I) . By far the lowest residual activities ofacid a-glucosidase were measured in fibroblasts from patients with severe, earlyonset forms of the disease. The enzymatic activity in fibroblasts from most adult patients was found to be substantially higher, with the exception of cell lines GM 1935, 84RD390, and E.M. In juvenile forms of glycogenosis type II, the activities were between the infantile and adult ranges. Essentially the same results were obtained with the artificial 4-methylumbelliferyl-a-glucoside substrate as with the natural substrate glycogen (Table I) . The activities of two other lysosomal enzymes, ,B-galactosidase and 3l-hexosaminidase, were normal in all mutant cell lines (not shown).
The biosynthesis ofacid a-glucosidase was studied in several of these mutant cell lines by pulse-chase labeling. For this purpose, the fibroblasts were grown in medium containing [3H]leucine, and acid a-glucosidase was immunoprecipitated and analyzed by SDS-polyacrylamide gel electrophoresis. Fig. 1 shows that in control cells acid a-glucosidase is synthesized as a precursor with an apparent molecular mass of 110 kD and is processed via a 95-kD intermediate to a major species of 76 kD. These conversions are completed within -8 h (14) . The faint bands with an apparent molecular weight of < 76 kD are contaminants that also appear when antibodies against ,B-hexosaminidase are employed. Fig. 1 also illustrates three examples of abnormal enzyme formation. In one patient with the infantile form of glycogenosis type II (266LAD) no acid a-glucosidase polypeptides were detectable. In contrast, the formation of the 1 10-kD precursor appeared undisturbed in two other mutants (460LAD, infantile, and 84RD390, adult), but here posttranslational processing to mature enzyme was impaired. The 95-kD intermediate form of acid a-glucosidase was present in cell line 460LAD but undetectable in cell line 84RD390 (Fig. 1) . Immunoblotting was used as a second alternative method to study the molecular forms of acid a-glucosidase in mutant cells. Fig. 2 illustrates the results obtained when this method was applied to the same cell lines as used in Fig. 1 . Preparations of acid a-glucosidase purified from human placenta and human urine served as reference samples. Human urine is enriched in precursor acid a-glucosidase and gives a strong signal at the 1 10 kD position (Fig. 2) (31) . Human placenta, on the other hand, contains mainly two mature forms of acid a-glucosidase with an apparent molecular mass of 76 kD and 70 kD (Fig. 2) . The molecular pattern of acid a-glucosidase as revealed by immunoblotting of control fibroblasts is similar to the one obtained via biosynthetic labeling except that the 76-kD band is relatively stronger and an additional molecular species of 70 kD is seen. The patterns in the mutant cell lines are also comparable using the two methods, but there are obvious differences. In the cell line 460LAD the 76-kD form of acid a-glucosidase is clearly visible by immunoblotting, and cross-reactive material is detectable in mutant 266LAD at the position of the 1 IO-kD precursor. This band in cell line 266LAD was further identified as the precursor of acid a-glucosidase by its positive reaction with antibodies directed against the 76-kD mature form of the enzyme (Fig. 2) .
The immunoblotting procedure was subsequently employed for the screening of a large number of mutant cell lines. The results are presented in Fig. 3 and Table I . Two distinct abnormalities in the formation of acid a-glucosidase were detected among 11 patients with an infantile form of the disease. In seven cases, the 1 l0-kD precursor of acid a-glucosidase was the only detectable band on immunoblots, as illustrated for 37 1LAD. Processed forms of the enzyme were visible in the remaining anti total acid dt-glucosidase (Fig. 3) . The acid a-glucosidase activity of these three cell lines was profoundly deficient, not only with the artificial substrate but also with the natural substrate glycogen.
The results are summarized in traced with an electron-dense complex of goat anti-rabbit IgG coupled to colloidal gold.
In the control cells the largest number of gold particles was found in the lysosomes (Fig. 4) . In addition, gold particles were detected in or near the cisternae of the rough endoplasmic reticulum (RER).' This intracellular compartment is recognized by the presence of limiting membranes that appear white on the picture and darker ribosomes surrounding these membranes (Fig.  4 A) . Furthermore, acid a-glucosidase was localized in the Golgi complex that was weakly labeled (Fig. 4 B) . Virtually no background labeling was observed with antibodies against human albumin, thus indicating the specificity of the labeling procedure.
Semiquantitative data on the lysosomal labeling were obtained by counting the number ofgold particles in 100 randomly chosen lysosomes (Fig. 5) . On the average, 11.5 gold particles were present in lysosomes of control cell line 81 RD238. With anti-albumin antibodies, this number was 0.03.
In Fig. 6 , the localization of acid a-glucosidase is compared in fibroblasts from three patients with infantile forms of the disease. In the cell line 266LAD (residual activity 0.5%), in which the 1 10-kD precursor was only detectable via immunoblotting (Fig. 2) but not via immunoprecipitation (Fig. 1) , acid a-glucosidase was predominantly found in the RER (Fig. 6 A) and in the Golgi complex (Fig. 6 B) . The intracellular localization of acid a-glucosidase in a second infantile variant (217LAD; residual activity, 0.3%) was very similar, although the molecular defect was shown to be different. In this case, the 110-kD precursor was detectable via both immunoblotting (pattern as for 371 LAD, Fig. 3 ) and immunoprecipitation (14) . However, the 1. Abbreviation used in this paper: RER, rough endoplasmic reticulum. 1692 Reuser, Kroos, Willemsen, Swallow, Tager, and Galjaard precursor ofthis mutant cell line has no phosphorylated mannose residues (14), whereas phosphorylation is considered to be essential for the transport of lysosomal enzymes to the lysosomes via the mannose 6-phosphate receptor (32, 34) . Also labeled lysosomes were difficult to find in this mutant, but the RER was weakly labeled, as in control cells (Fig. 6 C) 
(A) Localization of acid a-glucosidase in rough endoplasmic reticulum (R) and lysosomes (L). (B) Localization of acid aglucosidase in Golgi complex (G).
significantly more gold particles were encountered in cell line 75RD100, which showed trace amounts of95 and 76-kD enzyme protein on immunoblots (Fig. 6 D) . The residual activity (0.5%) was, however, very low. Interestingly, most of the lysosomal label appeared to be membrane associated. Semiquantitative data on the lysosomal labeling are presented in Fig. 5 . Figure 5 . Semiquantitative data on the labeling of lysosomes in fibroblasts from patients with glycogenosis type II in comparison with normal fibroblasts. Acid a-glucosidase was immunocytochemically labeled as described in Fig. 4 Two ofthe patients who were designated as juvenile variants (I24LAD and 77RD84) but differed in residual enzyme activity and molecular defect were studied. In cell line 124LAD (residual activity, 1.5%, Fig. 7 A) unlabeled lysosomes were more frequently found than in cell line 77RD84 (residual activity, 5.2%, Figs. 5 and 7 B) . Labeling of the RER and the Golgi complex Mi~~~~Z i in both cell lines appeared normal compared with control (see Fig. 7 C for cell line 124LAD). Fig. 8 is a composition ofelectron micrographs offibroblasts from three adult patients. The nature of the mutation in each of these variants was shown to be different. Cell line 196LAD (immunoblotting pattern as for 79RD 102, Fig. 3 ) had much higher residual activity (9.5%) than cell lines GM1935 (0.8%) and 84RD390 (3.0%), and this higher activity corresponded with the presence of mature forms of acid a-glucosidase. A phosphorylation defect was demonstrated in variant GM 1935 (14) , but phosphorylation was found to be normal in variant 84RD390 (A.J.J.R., unpublished results). Lysosomal labeling was frequently obtained in cell line 196LAD (Fig. 8 A) but much less often in GM1935 (Fig. 8 B) or in 84RD390 (Fig. 8 C) . These observations are shown semiquantitatively in Fig. 5 . Labeling ofthe RER ofGM 1935 appeared normal but the Golgi complex and its associated vesicular structures seemed to be labeled unusually strongly, when compared with several Golgi areas in normal and mutant cells (Fig. 8 D) . Unfortunately, semiquantitative data on the Golgi labeling could not be obtained. A characteristic feature of mutant GM 1935 was labeling of the cytoplasm, often in the vicinity of the plasma membrane (Fig. 8 E) . It was unclear with what type of cellular structure the label was associated.
Discussion
The cause of clinical diversity in glycogenosis type II was investigated by collecting detailed information on the biosynthesis, intracellular localization, and catalytic activity of mutant acid a-glucosidase in cultured fibroblasts from a large series of patients. The results obtained with the pulse-chase labeling or immunoblotting procedure turned out to be slightly different. The long-lived mature forms of acid a-glucosidase (70 and 76 kD) with an estimated half-life of 8-15 d (20) are quantitatively underestimated compared with precursor forms in relatively short pulse-chase periods. The immunoblotting procedure gives, in this respect, more accurate information on the actual amount of the various molecular species of acid a-glucosidase in the "steady state," and was chosen for comparing clinical variants.
A prominent finding is the reduced amount of mature enzyme protein in all 30 mutant cell lines. In view of the present results it is likely that the reduction of cross-reactive material, measured by Beratis et al. (1 1 (14) . Indeed, the labeling pattern is very similar to that of acid a-glucosidase in I-cell disease (29) where phosphorylation is hampered by deficiency of N-acetylglucosaminylphosphotransferase (32, 34 marily determined by the amount of functional acid a-glucosidase. However, the fact that some patients with a relatively mild phenotype have little enzyme in the lysosomes is puzzling. An explanation could be that the amount of functional enzyme is somewhat higher in the critical organs, heart, and skeletal muscle, due to subtle tissue differences in factors that affect the processing and intracellular transport ofthese particular mutant enzymes. Metabolic factors are likely to play a secondary role in the pathogenesis of the disease.
